News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

March 17, 2025

Lipidor announces all patients enrolled in ongoing Phase III study

STOCKHOLM, Sweden, 17th March 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that all patients in the ongoing Phase III study for the drug candidate AKP02G2 have been randomized. Lipidor now expects study results in the last week of May 2025. The main purpose of…

November 21, 2019

Correction: Lipidor AB (publ) publishes interim report for Q3 2019

The correction relates to the non-attached interim report for Q3 in the press release and the incorrect link to the interim report…

November 21, 2019

Lipidor AB (publ) publishes interim report for Q3 2019

Statement from Lipidor’s CEO Lipidor is experiencing considerable interest from both investors and the pharma industry, and in many meetings during the…

November 7, 2019

Lipidor Announces Last Patient Out in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis

Lipidor AB (publ) today reports that the last patient has completed treatment in the phase III study evaluating the efficacy of using…

September 23, 2019

Lipidor has been approved for listing on the Nasdaq First North Growth Market with first day of trading on September 27, 2019

Nasdaq Stockholm AB today approved the application of Lipidor AB ("Lipidor" or "the Company") for admission to trading of Lipidor shares and…

September 16, 2019

Lipidor’s New Share Issue Achieves 540 % Subscription

On Friday, 13 September 2019, the subscription period ended for Lipidor AB's ("the Company") issuance of units before the Company’s planned listing…

September 9, 2019

Lipidor Announces Enrolment of Last Patient in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis

Lipidor AB (publ) today reports that the last patient has been enrolled in the ongoing phase III study using calcipotriol spray against…

August 27, 2019

Lipidor AB publishes Information Memorandum in connection with a new issue of SEK 25.2 million prior to listing on Nasdaq First North Growth Market [updated]

The Board of Directors of Lipidor AB ("Lipidor" or "the Company") has decided to carry out a new issue of a maximum…

August 26, 2019

Lipidor AB publishes Information Memorandum in connection with a new issue of SEK 25.2 million prior to listing on Nasdaq First North Growth Market

The Board of Directors of Lipidor AB ("Lipidor" or "the Company") has decided to carry out a new issue of a maximum…

June 20, 2019

Decisions from Annual General Meeting of Lipidor AB, 20 June 2019

(Stockholm 20 June, 2019) On 20 June2019, the Annual General Meeting (”AGM”) of Lipidor AB (publ) was held in Stockholm. Read below for…

January 14, 2019

Lipidor AB successfully completes private placement of 20 MSEK

14 January 2019, Stockholm, Sweden. Lipidor AB, a Swedish drug development company with an ongoing fully financed Phase III study for a…